A575 two back translations of the English ItchRO. Cognitive interviews with five children with ALGS (patient report) and five parents (observer report) were to be performed. Key inclusion criteria were: children aged 5-9 years with cholestatic liver disease (ALGS) or progressive familial intrahepatic cholestasis (PFIC), who were also experiencing itching. Results: Recruitment was challenging and threatened to delay the clinical trial programme. Thus, recruitment was extended to include children who were 3-17 years of age, and in Spain and Germany, patients with alternative pathologies that manifested primarily with generalized pruritus were included. The final sample included: 15 with ALGS (France n= 5; Poland n= 5; Germany n= 3; Spain n= 2), 2 with PFIC (Spain), 2 with atopic dermatitis (Germany) and 1 with contact dermatitis (Spain). The ItchRO translations were well understood; there were no apparent differences in translation interpretations by disease state. ConClusions: Recruitment in linguistic validation projects in rare diseases can be a hurdle, yet patient understanding, rather than those of 'lay people, ' is preferable in paediatrics to ensure adequate interpretation, which can vary substantially across children. As a result patients with similar symptom and impact characteristics could be recruited if recruiting the primary population is likely to delay clinical trial research in rare diseases, where there is an urgent need for treatment.
objeCtives:
To determine NutriQoL ® responsiveness and minimal clinically important difference (MCID) in patients receiving HEN. Methods: NutriQoL ® , a specific questionnaire, developed and validated in Spain, for the assessment of HRQoL in patients receiving HEN regardless of the underlying condition was administered to a prospective cohort from 4 Spanish hospitals. It includes 17 pairs of items of HEN-related HRQoL, scoring from -51 (worst HRQoL) to 51 (best HRQoL). NutriQoL ® was completed three times within 1-month (±15 days) intervals (visit 1/visit 2/visit 3). Responsiveness was assessed by estimating the effect size and the standardized response mean between visits 1 and 3. For MCID calculation an anchor-based approach was performed. Interquartile range of the change in NutriQoL ® from patients, who reported changes in their health-status (worse or better) between visits 2 and 3, was used. Results: A total of 86 subjects who presented clinical changes between visits [63% male; mean (SD) age 61 (13)] participated. Cancer was the main diagnosis leading to HEN prescription (66.3%). NutriQoL ® scores were 16.98 (14.57), 16.63 (14.86) and 18.92 (15.25) for visit 1, 2 and 3, respectively. Up to 78.79% of patients reported improvements in their HRQoL since the introduction of HEN. The estimated effect size and the standardized mean response between visit 1 and 3 were 0.23 and 0.24. Regarding MCID, NutriQoL ® total scores difference between visit 2 and 3 in those patients that perceived changes in their health status was between -3.75 and 4.25 (interquartile range). ConClusions: NutriQoL ® responsiveness is moderate. This may be due to the limited temporal period between visits since most of patients referred improvements in their condition. A difference of ±4 points on NutriQoL ® total score regarding a previous administration demonstrates a clinical change that affects patients HRQoL.
PRM183 MeasuRing CHange in Quality of life: Can We distinguisH ReCall Bias and sCale ReCaliBRation?
Blome C. , Augustin M. University Medical Center Hamburg-Eppendorf, Hamburg, Germany objeCtives: Treatment effects on health-related quality of life (QoL) often differ depending on whether they are measured prospectively (before and after treatment) or retrospectively (after treatment only). It is not clear which of either evaluations is more valid: Prospective evaluations may be biased by scale recalibration (a changed understanding of the response scale), and retrospective evaluations may be biased by recall bias (a wrong assessment of former QoL). Methods: Based on an analysis of literature, we present an overview on (a) possible biases in prospective and retrospective measurement of QoL, (b) how these biases are named and defined in literature, and (c) current approaches to distinguish scale recalibration and recall bias. Results: The definitions of different biases are inconsistent. Many authors do not clearly distinguish measurement bias from true change. Furthermore, some consider only scale recalibration or only recall bias. There are different approaches for distinguishing scale recalibration and recall bias. We argue that these make too extensive assumptions to be valid. ConClusions: Much of the current discussion on the validity of prospective and retrospective QoL measurement suffers from unclear definitions, especially of "response shift" and "recall bias", or from neglecting one of the possible biases. We suggest more elaborate definitions for different types of bias, and recommend taking both kinds of bias into consideration when measuring change in QoL. Due to a lack of valid methods, there is not enough evidence on the extent of these biases yet; therefore the best approach for outcomes studies might be to include both prospective and retrospective assessments. In the long run, valid methods need to be developed to determine the most valid method of QoL assessment.
PRM184

MetHods to eliCit Patient PRefeRenCes: a Case study in MetastatiC BReast CanCeR
The patients are asked to complete the questionnaire at initial contact with the outpatient clinic and at four follow-up time points; one week, and one, three, and twelve months post-fracture). The last inclusion date will be December 31 st 2014. Results: The hypothesis is that the QUALIOST will provide a better estimate of the impact of osteoporosis-related fractures on HRQoL as it contains disease-relevant aspects, which may not be sufficiently covered in the generic EQ-5D-5L questionnaire. We will develop a mapping algorithm to predict EQ-5D derived utilities for Danish fracture patients from the QUALIOST, which can be used in future studies, where utilities then may be estimated from QUALIOST results. ConClusions: Mapping from QUALIOST scores to EQ-5D-5L derived utilities will enable estimation of preference-based HRQoL utilities for patients with osteoporotic fractures.
PRM179
RevieW of Patient-RePoRted outCoMes in diaBetiC MaCulaR edeMa
Ishii K. , Narimatsu A. , Adachi K. Bayer Yakuhin, Ltd., Tokyo, Japan objeCtives: Diabetic macular edema (DME) is a serious condition occurring in patients with diabetic retinopathy (DR) which is a common complication of diabetes. Understanding not only objective measurements such as visual acuity, but also the patients' perspective is important in gaining a comprehensive understanding of the impact of DME and its treatment on their functioning and well-being. The aim of this study is to understand possible measurements to investigate the impact of DME on health-related quality of life (HRQoL), by identifying currently available measurements, their ability to differentiate between DR and DME, and possible reasons for difficulties in measuring HRQoL specifically for DME. Methods: We performed a literature review on articles describing instruments of patient-reported outcomes (PRO) for DME. We summarized the current evidence on the usefulness of the instruments and whether they differentiate between DR and DME. In addition, we investigated possible hurdles in measuring HRQoL for DME, given the clinical understandings of the systemic aspects of DME. Results: We identified seven condition-specific or vision-specific measurements and seven general measurements including generic HRQoL and utilities for possible instruments for DME. However, realistic use for DME appears questionable even for vision-related measurements. The possible reasons could be that: 1) DME is not the primary disease, 2) many of DME patients have comorbidities such as DR, cataracts, and DR-induced glaucoma, and 3) those comorbidities itself may lead to decreased visual acuity with decreased HRQoL. ConClusions: Evidence is limited when measuring the impacts of DME on diabetic patients largely due to the lack of an effective PRO instrument for DME. The major difficulties in developing such instruments is that DME patients have complex health statuses, which provides for multiple reasons in decrease of QoL which may not be directly due to their DME.
PRM180 develoPMent of tHe BeHavioR Rating inventoRy of exeCutive funCtion -PResCHool veRsion (BRief-P) in 10 languages
Vasarri S. 1 , Isquith P. K. 2 1 Mapi, Lyon, France, 2 Dartmouth University, Norwich, VT, USA objeCtives: The Behavior Rating Inventory of Executive Function Preschool Version (BRIEF-P) was designed to provide a better understanding of preschool children's selfcontrol and problem-solving skills. It is composed of 63 items organized in five clinical scales which measure five aspects of executive functioning (Inhibit, Shift, Emotional Control, Working Memory, Plan/Organize). It is used to evaluate children aged 2-5 years old with a wide spectrum of developmental and acquired neurological conditions, such as learning disabilities, Tourette's disorder, traumatic brain injury, attention-deficit/ hyperactivity disorder or pervasive developmental disorders/autism. The objective of this study was to develop the BRIEF-P in 10 languages (Afrikaans, Bulgarian, Estonian, Greek, Japanese, Lithuanian, Romanian, Serbian, Slovak, Ukrainian). Methods: The following methodology was used: (1) Clarification of concepts with the developers; (2) Forward and backward translation steps in each target country. Results: The translation process did not reveal any cultural issues since most of the concepts assessed were cross-culturally relevant. The main difficulties consisted in finding conceptual equivalents of the original items with strong idiomatic content or containing words pertaining to the same semantic field. For instance, the most problematic items were items 10, 23 and 50. Item 23 (Is fidgety, restless, or squirmy) raised difficulties since it was not always possible to find direct equivalents for all adjectives in all languages. As for item 50 [Acts overwhelmed or overstimulated in crowded, busy situations (such as lots of noise, activity, or people)], discussions focused on how to convey the differences between "overwhelmed" and "overstimulated", as well as between "busy" and "crowded." In all cases, issues were solved with repeated discussions with the developers. ConClusions: The cross-cultural adaptation of the BRIEF-P into 10 languages required an international collaboration. The involvement of the developers during the whole process enabled the production of conceptually equivalent and culturally appropriate measures.
PRM181
CHallenges in ReCRuiting Patients foR tHe linguistiC validation of PRo instRuMents develoPed foR RaRe diseases: a Case study WitH alagille syndRoMe
Kennedy C. 1 , Abetz-Webb L. 2 , Lambe J. 3 1 Lumena, San Diego, CA, USA, 2 Patient-Centred Outcomes Assessments LTD, Macclesfield, Cheshire, UK, 3 Mapi, Lyon, France objeCtives: Observer and Patient Itch-reported Outcome Instruments (ItchRO) are electronic morning and evening diaries developed in US English to assess itchrelated symptom severity (rubbing, scratching, skin damage, sleep disturbances or irritability) in pediatric patients suffering from rare cholestatic liver diseases such as Alagille Syndrome (ALGS). Itching is a key symptom in ALGS and significantly impacts on a child's daily life. This research presents the recruitment challenges faced during the linguistic validation of the ItchRO into French, German, Polish and Spanish in ALGS patients. Methods: Native translators performed two forward and
